Small Cap Feast
Small Cap Feast – 29th November 2016
Dish of the Day:
No AIM Joiners Today
No AIM Joiners Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
Asia Pacific Investment Partner – the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December
RM Secured Direct Lending – The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m
Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December.
Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.
Mosman Oil & Gas (MSMN.L) 1.7p £3.5m
Mosman has updated on its proposed 90% acquisition of Pine Mills producing oil field located in Wood County, Texas. Mosman has today been advised by Cue Energy Resources that it will not close the acquisition with Mosman as the pre- emptive right held by a subsidiary of Gale Force has been exercised. Mosman has immediately referred this matter to its lawyers who are currently reviewing the contractual validity of the purported pre-emption.
Greatland Gold (GGP.L) 0.16p £2.53m
The precious and base metals exploration and development announced that drilling has commenced at its Warrentinna project in Tasmania, Australia. The current drilling programme includes plans for six angled reverse circulation (RC) drill holes each to a depth of 100 metres, for a total of approximately 600 metres of RC drilling; The current drilling programme will test for extensions to mineralisation at Derby North and test for mineralisation below historic workings in the Golden Mara area.
Crawshaw Group (CRAW.L) 22.5p £17.8m
The fresh meat and food-to-go retailer, notes the recent movement in its share price and confirm the Group continues to trade in line with management expectations. The LFL sales performance of the Group has improved from -15.8% for the first 7 weeks of H2 to -8.1% for the 4 weeks ended 27 November 2016 driven by a 13% improvement in customer numbers. Expects rate of improvement in LFL sales to further improve in December as returning customer’s trade across the breadth of its seasonal offer and existing customers benefit from better value Xmas meat hampers and redeeming their savings club cards. On less than 0.5x FYJan17 revenue.
CityFibre Infrastructure Hldgs (CITY.L)56.5 p £150.1m
The designer, builder, owner, and operator of fibre optic infrastructure in UK towns and cities, announced that it has begun a roll-out of dense full-fibre networks in business parks across its 40 city UK footprint to reach more than 500 business parks. Over 22,000 SMEs will benefit from low-cost access to world-class, gigabit-speed internet services delivered over the new infrastructure in or near CityFibre’s existing networks. The first parks targeted for upgrade are in the Company’s Gigabit City projects Coventry, Bristol and Peterborough. FYDEC16E rev £15m, pre-tax loss £10.6m.
IG Design Group (IGR.L) 276.5p £173.2m
H1Sep16 results from the designers, innovators and manufacturers of gift packaging, greetings, stationery, creative play products and giftware. Sales up 21.5% to £145.5m. GP up 40.8% to £30.8m. Underlying Earnings Per Share up 50.0% to 9.6p . ‘With a substantial order book in place for the remainder of the year, we are on course to deliver a full year financial performance ahead of market expectations. Further we are sufficiently confident with the prospects for profits growth and cash generation to increase the total dividend expectation for the full year to 4p’
Ergomed (ERGO.L) 132.5p £52.82m
The pharmaceutical services and drug development company, today announces the acquisition of European PharmInvent Services s.r.o. (“PharmInvent”), a leading European pharmacovigilance and regulatory services busines. Initial consideration of €4.8m, with contingent consideration based on the achievement of EBITDA targets for 2016, 2017 and 2018 of up to €3.2m. 80% cash. 20% shares. IN FY2015 PharmInvent reported revenue of €3.0million and adjusted EBITDA of €0.7million. ERGO FYDec16E rev of £35.85m and PBT of £1.67m.
LGO Energy (LGO.L) 0.11p £8.21m
LGO today confirmed the successful conclusion of negotiations for the sale of over 10,000 barrels of oil stocks in Spain. The oil has been sold at a price competitive with local fuel oil, and the funds generated will be used in CPS operations and general corporate working capital. In separate news from the Ayoluengo Field, the CPS-owned workover rig has recently undergone a two yearly mechanical recertification and has now been returned to service.
Judges Scientific (JDG.L) 1347.5p £82.3m
The group involved in the buy and build of scientific instrument businesses, announces that it has today acquired 100% of the issued share capital of EWB Solutions Ltd, a maker of scientific devices based in Hemel Hempstead, Hertfordshire. EWB manufactures edge-welded bellows used in Ultra High Vacuum (“UHV”) systems and various other applications. The Board expects the Acquisition to be immediately earnings enhancing. Cash consideration of £1.76m. Vs FYApr16 rev of £1.2m and PBT of £0.5m. Financed by Lloyds facility. On a FYDec16E PE of 16.7x.
Versarien (VRS.L) 12.5p £14.98m
The advanced materials group, has announced the receipt of a further significant graphene order for a carbon fibre composite related OEM application. Versarien has now received an order with a value of over £100,000 for graphene in the form of Few Layer Graphene Nano Platelets (“GNPs”) from a European commercial customer, in conjunction with the National Graphene Institute. FY Mar 17E revenues of £7.6m and pre-tax loss of £0.3m.
Cyprotex (CRX.L) 159.25p £35.85m
The specialist ADME-Tox Contract Research Organisation (CRO), today announces the launch of h-CLAT (human Cell Line Activation Test), an in vitro service for determining skin sensitisation potential. Cyprotex have developed this test in response to the recently released OECD (Organisation for Economic Co-operation and Development) test guideline 442E. The European Union, along with many other countries throughout the world, have now implemented a complete ban on animal testing within the cosmetics industry. There are no market forecasts.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.